Endocyte — Merger or Acquisition (October 2018)
8 slides from Endocyte's merger presentation, Oct 18, 2018
Slide 1: Disclaimer
Disclaimer 2 This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or
Slide 2: Novartis announces agreement to acquire Endocyte, expanding nuclear medicines platform
3 Novartis announces agreement to acquire Endocyte, expanding nuclear medicines platform1 High unmet need in prostate cancer Prostate cancer expected to be USD 11bn market globally in 20242 177Lu-PSMA-617 expected to provide an additional treatment option, in particular for refractory patients First
Slide 3: 177Lu-PSMA-617 uses a small molecule ligand to target a radioactive atom to PSMA-expressing cancer cells
4 177Lu-PSMA-617 uses a small molecule ligand to target a radioactive atom to PSMA-expressing cancer cells Source: Endocyte Investor Presentation October 2018 RLT that utilizes high affinity targeting ligand to direct potent radiotherapy to prostate cancer cells 177Lu-PSMA-617 pairs PSMA targeting l
Slide 4: Strong Ph2 clinical data
5 Strong Ph2 clinical data PSA PFS 50 patients Overall Survival First 30 patients Patients PSA response % Sustained response rates in Ph2 trial expansion1 PSA PFS and OS correlate to PSA response and compare favorably to historical benchmarks1 Months p-value comparing PSA <50% group to PSA > 50% gro
Slide 5: Pivotal Ph3 VISION trial design with FDA agreement to rPFS as alternative primary endpoint
6 Pivotal Ph3 VISION trial design with FDA agreement to rPFS as alternative primary endpoint to OS1 177Lu-PSMA-617 Choice of NAAD3 or not Best supportive care2 Best supportive care2 Choice of NAAD3 or not 2:1 Stratified for balance Source: Endocyte Investor Presentation October 2018 1. Endocyte stat
Slide 6: Transaction highlights
7 Transaction highlights Financing Funded through existing cash Financial Benefits Expected to contribute to Group sales in 2021 Expected IRR well in excess of cost of capital Other Transaction unanimously approved by the Boards of Directors of both companies Closing is subject to Endocyte stockhold
Slide 7: Expected next steps
8 Expected next steps Endocyte to file a preliminary proxy statement with the SEC relating to a shareholders meeting to be held to obtain shareholders approval of the transaction Closing by H1 2019, subject to an affirmative vote by Endocyte’s stockholders to adopt the merger agreement and satisfact
Slide 8: Expected next steps
Expected next steps = Publications on other ongoing investigator initiated clinical trials of 77Lu-PSMA-617 in prostate cancer patients expected in 2018 Endocyte development and regulatory status = Endocyte stated rPFS endpoint expected end 2019 and final OS endpoint end 2020" = — Endocyte to file a